Recombinant vaccine production in yeast

BioPharm International

Volumn 21, Issue 1 SUPPL., 2008, Pages 8-13

  Melmer, Georg ^a   Kunze, Gotthard ^b   Gellissen, Gerd ^a  

^a PharmedArtis GmbH   (Germany)

^b IPK Gatersleben ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; ENIVAC HB; GENE VAC B; HEPATITIS B VACCINE; HEPAVAX GENE; HIRUDIN; INSULIN; PROBIVAC; RECOMBINANT HEPATITIS B VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

DRUG FORMULATION; DRUG MANUFACTURE; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HANSENULA POLYMORPHA; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNIZATION; METHYLOTROPH; PAPILLOMA VIRUS; PICHIA PASTORIS; REVIEW; SACCHAROMYCES CEREVISIAE; VERRUCA VULGARIS; VIRUS PARTICLE; YEAST;

EID: 39149119655     PISSN: 1542166X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Melmer G. Biopharmaceuticals and the industrial environment. Gellissen G, editor. In: Production of recombinant proteins. Weinheim, Germany: Wiley VCH;2005, pp. 319-359.
2. Goeddel D, et al. Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone. Nature. 1979a;281:544-8.
3. Goeddel D, Kleid DG, Bolivar F. Expression in E. coli of chemically synthesized genes for human insulin. Proc Natl Acad Sci USA. 1979b; 76:106-110.
4. Cutts FT, et al. Human papillovirus and HPV vaccines: a review. Bull World Health Org. 2007; 719-726.
5. Harford N, Cabezon T, Coiau B, Delisse A-M, Rutgers T, De Wilde M. Construction and characterization of a Saccharomyces cerevisiae strain (RIT4376) expressing hepatitis B surface antigen. Postgrad Med J. 1987;63:65-70.
6. Schaefer S, Piontek M, Ahn S-J, Papendieck A, Janowicz ZA, Timmermans I, Gellissen G. Recombinant hepatitis B vaccines - disease characterization and vaccine production. Gellissen G, editor. In: Hansenula polymorpha - biology and applications. Weinheim, Germany: Wiley VCH;2002, pp. 185-210.
7. Brocke P, et al. Recombinant hepatitis B vaccines: disease characterization and vaccine production. Gellissen G, editors. In: Production of recombinant proteins. Weinheim, Germany: Wiley VCH;2000, pp. 319-359.
8. Gleeson M, Ortori S, Sudbery P. Transformation of the methylotrophic yeast Hansenula polymorpha. J Gen Microbiol. 1986; 132:3459-3465.
9. Roggenkamp R, Hansen H, Eckart M, Janowicz Z, Hollenberg C. Transformation of the methylotrophic yeast Hansenula polymorpha by autonomous replication and integration vectors. Mol Gen Genet. 1986;202:302-308.
10. Gellissen G, et al. Die methylotrophe Hefe als Expressionssystem für heterologe Proteine BioEngin. 1990;5:20-26.
11. Hollenberg CP, Gellissen G. Gene expression in methylotrophic yeasts. Curr Opin Biotechnol. 1997;8:554-60.
12. Gellissen G, Hollenberg CP. Application of yeasts in gene expression studies: a comparison of Saccharomyces cerevisiae, Hansenula polymorpha and Kluyveromyces lactis - a review. Gene. 1997;190:87-97.
13. Gellissen G, Hollenberg CP. Hansenula. Robinson R, Batt CA, Patel PD, editors. In: Encyclopedia of Food Microbiology. Vol. 2. San Diego, CA: Academic Press;1997, pp. 976-982.
14. Gellissen G. In: Hansenula polymorpha - biology and applications. Weinheim, Germany: Wiley VCH;2002.
15. Gellissen G, Melber K. Methylotrophic yeast Hansenula polymorpha as production organism for recombinant pharmaceuticals. Arzneim Forsch/Drug Res. 1996;46:943-8.
16. Dane DS, Cameron CH, Briggs M. Virus like particles in serum of patients with Australia-antigen-associated hapatitis. Lancet. 1970;1:695-698.
17. Blumberg BS, Sutnick AI, London WT. Hepatitis and leukemia: their relation to Australia antigen. Bull. NY Acad Med. 1968;1566-1586.
18. Mahoney FJ. Update on Diagnosis, Management, and Prevention of Hepatitis B Virus Infection. Clin Microbiol Rev. 1999;12:351-366.
19. Zuckerman JN, Zuckerman AJ. Current topics in hepatitis B. J Infect. 2000;41:130-136.
20. Norder H, Couroucé AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology. 1994;489-503.
21. Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, Rossau R. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol. 2000;81:67-74.
22. Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol. 2002;83:2059-73.
23. Naumann H, Schaefer S, Yoshida CF, Gaspar AM, Re R, Gerlich WH. Identification of a new hepatitis B virus HBV genotype from Brazil that expresses HBV surface antigen subtype adw4. J Gen Virol. 1993;74:1627-32.
24. Norder H, Arauz-Ruiz P, Blitz L, Pujol FH, Echevarria JM, Magnius L. The T1858 variant predisposing for the pre-core stop mutation correlates with one of two major genotype F hepatitis B virus clades. J Gen Virol. 2003;84:2083-7.
25. Jursch CA. Größenbestimmung von Viren in menschlichen Blutplasma durch Ausschlußchromatographie. 2000; Universität of Gießen, Germany.
26. Crowther RA, Kiselev NA, Böttcher B, Berriman JA, Borisova GP, Ose V. Three-dimensional structure of hepatitis B virus core particles determined by electron cryomicroscopy. Cell. 1994;77:943-950.
27. Heermann KH, Gerlich WH. Surface Proteins of Hepatitis B Viruses. MacLachlan A, editor. In: Molecular Biology of the Hapatitis B Virus. Boca Raton: FLCRC Press;1991, pp. 109-143.
28. Kann M, Bischof A, Gerlich W. In vitro model for the nuclear transport of the hepadnavirus genome. J Virol. 1997;71:1310-6.
29. Kann M, Gerlich WH. Hepatitis B. Mahy BWJ, Collier L, editors. In: Virology. London: Arnold;1998, pp. 745-773.
30. Nassal M, Schaller H. Hepatitis B virus replication - an update. J Viral Hepatitis. 1996;3:217-226.
31. Brechot C, et al. Impact of HBV, HCV, and GBV C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. J Hepatol. 1998;29:173-83.
32. Buendia MA, Paterlini P, Tiollais P, Brechot C. Hepatocellular carcinoma: molecular aspects. Zuckerman AJ, Thomas CT, editors. In: Viral Hepatitis. Livingstone, London: Churchill;1998, pp. 179-200.
33. Kang HA, Gellissen G. Hansenula polymorpha. Gellissen G, editor. In: Production of recombinant proteins. Weinheim, Germany: Wiley VCH;2005, pp. 319-359.
34. Rutgers T, et al. Expression of different forms of hepatitis B virus envelope proteins in yeast. Zuckerman A, editor. In: Viral Hepatitis and Liver Disease. New York: A. R. Liss;1988, pp. 304-308.
35. Dupont J, et al. A controlled clinical trial comparing nthe safety and immunogenicity of new adjunvanted hepatitis B vaccine with a standard hepatitis B vaccine. Vaccine. 2006;24:7167-74.
36. Cooper CL, et al. CPG7909 improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS. 2005;19:1473-79.
37. Lobaina Y, Palenzuela D, Pichardo D, Muzio V, Guillén G, Aguilar JC. Immunological charcaterization of two hepatitis B core antigen variants and their immunoenhancing effect on codelivered hepatitis B surface antigen. Mol Immunol. 2005;42;289-294.
38. Zhang Q, Xue X, Qu L, Pan W. Construction and evaluation of a multistage combination vaccine against malaria. Vaccine. 2007;25:2112-9.
39. Webb RP, Smith TJ, Wright PM, Montgomery VA, Meagher MM, Smith LA. Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins. Vaccine. 2007:25:4273-82.